Calls
2
Andrew Huberman
Professor of Neurobiology and Ophthalmology, Stanford University; Host, Huberman Lab
Win Rate
100.0%
return
+10.8%
Ticker
Side
Mentions
First Call
Call Price
P&L
Thesis
Theme
Source
Long
Mar 09
$1001.20
+15.1%
Retatrutide, Lilly's GLP-3, showed phase 3 weight loss up to a third of body weight with some muscle sparing and fewer side effects. It is already being sold by compounding and gray market sources, and Lilly is working to control compounding.
GLP-1 / Obesity
Long
Mar 09
$34.14
+6.5%
Nearly one in seven Americans take a GLP-1 and 20% have tried them. Adoption will rise, possibly over half of Americans, especially those with family obesity, often at lower doses via compounding/gray market. In theory, obesity could be eradicated.
Thematic ETFs
Showing 2 of 2 calls · sorted by mentions
Choose a mentions count to open ticker posts.
Andrew Huberman has 2 trade ideas tracked on Buzzberg across 2 tickers since March 2026. Most covered: LLY, RETATRUTIDE, CONTINUOUS GLUCOSE MONITORS.
Historical call returns are modeled from recorded ideas and stored prices, not actual brokerage portfolio returns. Check the evaluated call set and horizon; past results do not establish future prediction accuracy. Explore our data and methodology
